TJTuomas Jartti

Tuomas Jartti

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tuomas Jartti has a total of 807 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Rhinovirus: Too Bad to Be True

    by Tuomas Jartti, Heidi Makrinioti, Wojciech Feleszko

    Was not provided for this article.

  • Top Cited Papers
    Open Access

    Allergic Rhinitis and Its Impact on Asthma ( ARIA )‐ EAACI Guidelines—2024–2025 Revision: Part II —Guidelines on Oral and Ocular Treatments

    by Rafael José Vieira, Bernardo Sousa‐Pinto, Jean Bousquet, Holger J. Schünemann, Torsten Zuberbier, Antonio Bognanni, Alkis Togias, Boleslaw Samolinski, Arunas Valiulis, Sian Williams, et al.

    Background: Oral and ocular medications are frequently used in the treatment of allergic rhinitis (AR). As part of the update of the Allergic Rhinitis and its Impact on Asthma (ARIA)‐EAACI guidelines, this manuscript presents the ARIA‐EAACI 2024–2025 recommendations for oral and ocular treatments. Methods: The ARIA‐EAACI 2024–2025 guideline panel issued recommendations following the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) evidence‐to‐decision framework. Several sources of evidence were used to inform panel judgements and recommendations, including systematic reviews, mHealth and pharmacovigilance data as well as a survey on costs. Results: Eight guideline questions concerning oral treatments for AR and three questions concerning ocular treatments were addressed. These questions led to the recommendations. Overall, these questions concern the choice between different classes of medication. They also discuss the role of oral antihistamines (OAH), leukotriene receptor antagonists (LTRA), ocular antihistamines (OcAH) and ocular mast cell stabilisers. Four questions had not been previously evaluated in ARIA guidelines, while, for the other four, there was a change in the strength or directionality of the recommendations. Overall, these guidelines recommend using intranasal corticosteroids over OAH and using OAH over LTRA. Moreover, they suggest using OAH over OcAH and suggest being against adding LTRA to OAH. Finally, considerations for choosing between different individual OAHs are presented. Conclusion: This ARIA‐EAACI 2024–2025 article supports patients, their caregivers and healthcare professionals in choosing oral and ocular treatments for AR. Decisions on treatment should consider the clinical variability of the disease, patients' values and the affordability of medications.


  • Open Access

    A SynAir‐G Position Statement for the Improvement of Indoor Air Quality for Children

    by Kristina Siemens, Tamar Abramidze, Cezmi Akdis, Mübeccel Akdis, Isabella Annesi Maesano, Nikos Antoniou, Stathis Antoniou, Sylvie Broussous, Davide Caimmi, Yash Chadha, et al.

    Air pollution has been recognised as the single biggest environmental threat to human health within the European Union (EU). Indoor air pollution has received less attention than outdoor air pollution, even though we spend most of our time indoors. It is associated with a variety of short‐ and long‐term health effects. These include allergies and asthma with a key role for the exposure to bioaerosols and synergistic interactions between chemical and biological pollutants. Given the dramatic rise of allergic diseases, the prevention of symptom exacerbations and the new onset of disease are of great importance, particularly for vulnerable populations such as children. The lack of a unified EU‐wide approach involving all stakeholders represents a major unmet need. The EU‐funded IDEAL Cluster comprises seven research projects to advance knowledge on indoor air quality (IAQ) and its impact on health, inform policies and thus promote healthier indoor environments. The ‘SynAir‐G’ project forms part of this cluster and was launched in 2022 with the participation of 18 partners from 11 countries. It focuses on schools to explore synergistic interactions between chemical and biological pollutants based on the hypothesis that these modulate major health effects. SynAir‐G includes the development of low‐cost sensors, collection of health outcomes, modelling of pollution dynamics and the development of mitigation solutions. The knowledge will be circulated to all stakeholders and the public aiming to establish standards and health‐based guidelines. The scope of this position statement is (1) to review the current evidence on indoor air pollution, its impact on health and particularly on children with allergies and asthma; (2) to give an overview of the European regulatory framework; (3) to describe knowledge gaps, challenges and unmet needs; and (4) to present SynAir‐G′s project goals and propose a roadmap to improve IAQ for children with asthma and allergies.

  • Open Access

    Exposures in Indoor Air Affecting Health

    by Maria Hartiala, Varpu Elenius, Alicia Aguado Pesquera, Silas Androulakis, Isabella Annesi‐Maesano, Artur Badyda, Sicco Brandsma, Ioanna Chatziprodromidou, Goran Gajski, Judith Garcia‐Aymerich, et al.

    Indoor air quality (IAQ) is influenced by a wide range of chemical, biological and physical agents that can negatively impact physical, immunological and mental health. Adverse health effects depend on the type and concentration of pollutants, duration of exposure, and individual susceptibility. The availability of data on IAQ is limited, as are standardized approaches for evaluating its health impact. This expert review aims to describe the most important indoor air determinants affecting health, and present the IDEAL cluster, which comprises seven EU‐funded scientific projects on the topic of IAQ and human health. Across the IDEAL projects, knowledge is generated on exposure to a wide range of indoor air pollutants, including well‐known hazards and more explorative chemical and microbiological determinants. The projects will also contribute to the implementation of low‐cost and/or real‐time sensors on IAQ, as well as advanced chemical and microbiological analyses, and evaluate various interventions to improve IAQ. Several of them focus on particularly vulnerable groups. Raising public awareness and implementing measures to reduce pollutant levels are essential for safeguarding health, particularly in urban areas with elevated pollution levels.


  • Top Cited Papers
    Open Access

    Allergic Rhinitis and Its Impact on Asthma ( ARIA )‐ EAACI Guidelines—2024–2025 Revision: Part I—Guidelines on Intranasal Treatments

    by Bernardo Sousa‐Pinto, Jean Bousquet, Rafael José Vieira, Holger J. Schünemann, Torsten Zuberbier, Antonio Bognanni, Alkis Togias, Boleslaw Samolinski, Arunas Valiulis, Sian Williams, et al.

    Background: Allergic rhinitis (AR) impacts quality of life, work and school productivity. Over the last years, an important body of evidence resulting from mHealth data has led to a better understanding of AR. Such advances have motivated an EAACI‐endorsed update of the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines (ARIA 2024–2025). This manuscript presents the ARIA 2024–2025 recommendations for intranasal treatments, one of the mainstays for AR management. Methods: The ARIA 2024–2025 guideline panel issued recommendations following the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) evidence‐to‐decision framework. Several sources of evidence were used to inform panel judgments and recommendations, including systematic reviews, evaluation of mHealth and pharmacovigilance data, as well as a survey of experts on costs. Results: Eleven guideline questions concerning intranasal treatments for AR were prioritized, leading to recommendations. Overall, these questions concern the choice between different classes of intranasal medications—most notably, intranasal corticosteroids (INCS), antihistamines (INAH), fixed combinations of INAH+INCS and decongestants—or between different individual medications within each class. Four questions had not been evaluated in previous ARIA guidelines, while for the other three there was a change in the strength or directionality of recommendations. Overall, recommendations point to the suggested use of INAH+INCS over INAH or INCS and INCS over INAH. Conclusion: This ARIA 2024–2025 article supports patients, their caregivers, and healthcare professionals in choosing an intranasal treatment. However, decisions on AR treatment should consider the clinical variability of the disease, patients' values, and the affordability of medications.


  • Open Access

    Methodology for the Development of the Allergic Rhinitis and Its Impact on Asthma ( ARIA )‐EAACI 2024–2025 Guidelines: From Evidence‐to‐Decision Frameworks to Digitalised Shared Decision‐Making Algorithms

    by Jean Bousquet, Bernardo Sousa‐Pinto, Rafael José Vieira, Holger J. Schünemann, Torsten Zuberbier, Antonio Bognanni, Alkis Togias, Boleslaw Samolinski, Arunas Valiulis, Sian Williams, et al.

    The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines produced their first edition in 1999, with subsequent revisions in 2008, 2010, 2016 and 2019. A new iteration of ARIA—ARIA 2024–2025—in collaboration with EAACI is currently being developed, focusing on the management of allergic rhinitis. ARIA 2024–2025 follows the GRADE framework and is endorsed by the European Academy of Allergy and Clinical Immunology (EAACI). A set of approaches has been used to develop guideline questions, including surveying key opinion leaders and using artificial intelligence (AI)‐based tools to analyse web searches on allergic rhinitis and to generate questions. Each prioritised guideline question is assessed through an Evidence‐to‐Decision (EtD) framework. EtDs support the systematic and transparent formulation of recommendations, comprising 12 criteria for which the best available evidence should be sought. In the context of ARIA‐EAACI 2024–2025, such evidence is derived not only from randomised controlled trials but also—among others—from patient‐generated data sources that better reflect the affected individuals' perspectives. Moreover, ARIA‐EAACI 2024–2025 incorporates evidence on planetary health. Developed guideline recommendations will support the creation of digitalised decision algorithms and care pathways. This paper describes the methodology used to develop the person‐centred, digitally enabled and AI‐assisted ARIA‐EAACI 2024–2025. Among others, it describes (i) the development and prioritisation of guideline questions, (ii) sources of evidence for EtDs and (iii) the development of digitalised decision algorithms and care pathways.


  • Open Access

    A Diagnostic Approach to Separate Acute Human Bocavirus 1 Respiratory Tract Infection From Long-lasting Virus Shedding

    by Rajita Rayamajhi Thapa, Cristiana Nascimento-Carvalho, Tobias Allander, Tuomas Jartti, Maria Söderlund-Venermo

    Human bocavirus 1 (HBoV1) causes mild to life-threatening respiratory tract infections in children but may persist in the airways for months. Currently used polymerase chain reaction may thus lead to false diagnoses and irrelevant codetections. Our aim was to differentiate acute infections from persistent shedding by pretreatment of airway or serum samples with an endonuclease, followed by polymerase chain reaction (ePCR). We show that HBoV1 DNA is protected by a capsid in the acute phase but not in persistent shedding, and we provide proof of concept of a novel test that may be applied in routine diagnosis of acute HBoV1 respiratory tract infection for more accurate results.


  • Early‐life exposure to residential greenness and risk of asthma in a U.S. bronchiolitis cohort

    by Wojciech Feleszko, Heidi Makrinioti, Marta Nalej, Tadao Ooka, Zhaozhong Zhu, Ashley F. Sullivan, Tuomas Jartti, Kohei Hasegawa, Carlos A. Camargo

    Introduction: Severe bronchiolitis (i.e., bronchiolitis requiring hospitalization) is linked to childhood asthma development. Despite a growing understanding of risk factors for developing post‐bronchiolitis asthma, protective factors remain unclear. In this study, we aimed to investigate whether exposure to residential greenness between birth and bronchiolitis hospitalization is associated with asthma and atopic asthma development by age 6 years.Methods: We analyzed a US severe bronchiolitis cohort from hospitalization to age 6 years, investigating how the normalized difference vegetation index (NDVI) and chlorophyll index green (CI green), measured in small (100 m) and large (500 m) radiuses around homes, relate to asthma and atopic asthma by age 6 years. We also explored whether maternal antibiotic use, daycare attendance, and respiratory virus type during hospitalization act as effect modifiers.Results: The study cohort included 861 infants, with 239 (28%) developing asthma by age 6 years—152 atopic, 17 nonatopic, and 70 unclassified. Early life residential exposure to high NDVI and CI green levels was associated with lower odds of asthma (ORAdj for NDVI within a 100 m radius, 0.18; 95% CI, 0.05–0.78; and ORAdj for CI green levels within a 100 m radius, 0.53; 95% CI, 0.31–0.90). Associations also were significant for the development of atopic asthma (ORAdj 0.16; 95% CI, 0.03–0.96; and ORAdj 0.46; 95% CI, 0.25–0.92; respectively). Results were similar for the 500 m radius exposures. No effect modification was noted.Conclusion: In a U.S. bronchiolitis cohort, exposure to residential greenness between birth and bronchiolitis hospitalization is linked to lower asthma and atopic asthma risk by age 6 years.


  • Open Access

    B cell immune response to human bocaviruses

    by Cagatay Karaaslan, Oliver Wirz, Ge Tan, Anna Globinska, Tadech Boonpiyathad, Klaus Hedman, Slavica Vaselek, Maria Söderlund Venermo, Tuomas Jartti, Mubeccel Akdis, et al.

    Background: Human bocaviruses (HBoVs) have been demonstrated in respiratory and gastrointestinal infections; however, the immune response to them has not been studied in detail. In this study, we investigated the B cell immune responses to HBoV1 and HBoV2, representing two different species of bocaviruses in humans. Methods: We analyzed the effects of stimulations with HBoV1 and 2 virus‐like particles (VLPs) and of co‐stimulation with HBoV1‐rhinovirus (RV) on cells of the immune system by flow cytometry, transcriptomics, and luminometric immune assays. Results: Human B cells, and particularly B regulatory cells (Breg cells), showed an increased immune response to HBoV1‐VLPs stimulation. These immune responses were also supported by increased IL‐1RA and PDL1 expressions in IL‐10 + B cells from peripheral blood mononuclear cells (PBMCs) stimulated with HBoV1‐VLPs. In addition, increased levels of IL‐10 and IL‐1RA were determined in the supernatants of PBMCs following HBoV1‐VLPs stimulation. HBoV1‐VLPs and RV co‐stimulation increased the IL‐10 + B cell population. Transcriptome analysis by next‐generation RNA sequencing showed an increased expression of IL‐10 signalling and Breg cell markers in PBMCs stimulated with HBoV1‐VLPs. Furthermore, TGF‐β and chemoattractants MIP‐1α, MIP‐1β and IP10 protein levels were high in the supernatants of PBMCs stimulated with HBoV1‐VLPs. Conclusions: The findings demonstrate that in Breg cells, IL‐10 signalling pathways, and anti‐inflammatory activity are induced by HBoV1, which can explain the often mild nature of the disease. In addition, the immune regulatory response induced by HBoV1‐VLPs may indicate a potential immunomodulatory role of HBoV1 on the immune system and may represent an immune regulatory strategy.


  • Open Access

    Addressing adverse synergies between chemical and biological pollutants at schools—The ‘SynAir‐G’ hypothesis

    by Nikolaos G. Papadopoulos, Cezmi A. Akdis, Mubeccel Akdis, Athanasios Damialis, Giuseppina Esposito, Ioana Fergadiotou, Christian Goroncy, Pierre Guitton, Maia Gotua, Kleanthis Erotokritou, et al.

    While the number and types of indoor air pollutants is rising, much is suspected but little is known about the impact of their potentially synergistic interactions, upon human health. Gases, particulate matter, organic compounds but also allergens and viruses, fall within the ‘pollutant’ definition. Distinct populations, such as children and allergy and asthma sufferers are highly susceptible, while a low socioeconomic background is a further susceptibility factor; however, no specific guidance is available. We spend most of our time indoors; for children, the school environment is of paramount importance and potentially amenable to intervention. The interactions between some pollutant classes have been studied. However, a lot is missing with respect to understanding interactions between specific pollutants of different classes in terms of concentrations, timing and sequence, to improve targeting and upgrade standards. SynAir‐G is a European Commission‐funded project aiming to reveal and quantify synergistic interactions between different pollutants affecting health, from mechanisms to real life, focusing on the school setting. It will develop a comprehensive and responsive multipollutant monitoring system, advance environmentally friendly interventions, and disseminate the generated knowledge to relevant stakeholders in accessible and actionable formats. The aim of this article it to put forward the SynAir‐G hypothesis, and describe its background and objectives.